Nijmegen Breakage Syndrome Clinical Trial
Official title:
Clinical Open-label Phase 2 Study of Low Dose Treosulfan Based Conditioning Regimen Efficacy in Hematopoietic Stem Cell Transplantation for Children With Nijmegen Breakage Syndrome
The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT in Nijmegen breakage syndrome
Status | Recruiting |
Enrollment | 10 |
Est. completion date | May 2023 |
Est. primary completion date | May 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Months to 21 Years |
Eligibility |
Inclusion Criteria: 1. Patients aged = 3 months and < 21 years 2. Patients diagnosed with NBS eligible for an allogeneic HSCT 3. Signed written informed consent signed by a parent or legal guardian |
Country | Name | City | State |
---|---|---|---|
Russian Federation | HSCT department | Moscow |
Lead Sponsor | Collaborator |
---|---|
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event-free survival | Events: graft failure, death, malignancies | 3 years after HSCT | |
Secondary | Overall survival | 3 years after HSCT | ||
Secondary | Cumulative incidence of engraftment | 100 days | ||
Secondary | Cumulative incidence of graft failure | 3 years | ||
Secondary | Cumulative incidence of viral infections | 1 year | ||
Secondary | Cumulative incidence of acute graft versus host disease | 1 year | ||
Secondary | Cumulative incidence of chronic graft versus host disease | 3 years | ||
Secondary | Incidence of early organ toxicity | 100 days | ||
Secondary | Cumulative incidence of transplant related mortality | 3 years | ||
Secondary | Incidence of long-term toxicity | malignancies, non-malignant complications | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06198842 -
Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome
|
Phase 2 |